Tokyo - Delayed Quote JPY

Healios K.K. (4593.T)

161.00 -4.00 (-2.42%)
At close: June 7 at 3:15 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
124,000.00
121,000.00
90,000.00
41,000.00
27,000.00
--
Cost of Revenue
--
13,000.00
--
--
--
--
Gross Profit
112,000.00
109,000.00
90,000.00
41,000.00
27,000.00
--
Operating Expense
3,652,000.00
3,488,000.00
5,269,000.00
5,425,000.00
4,211,000.00
--
Operating Income
-3,540,000.00
-3,379,000.00
-5,179,000.00
-5,384,000.00
-4,184,000.00
--
Net Non Operating Interest Income Expense
-1,863,000.00
-248,000.00
-154,000.00
926,000.00
-1,181,000.00
--
Pretax Income
-5,402,000.00
-3,626,000.00
-5,330,000.00
-4,462,000.00
-5,378,000.00
--
Tax Provision
102,000.00
187,000.00
-160,000.00
450,000.00
135,000.00
--
Net Income Common Stockholders
-5,515,000.00
-3,823,000.00
-5,169,000.00
-4,910,000.00
-5,512,000.00
--
Diluted NI Available to Com Stockholders
-5,515,000.00
-3,823,000.00
-5,169,000.00
-4,910,000.00
-5,512,000.00
--
Basic EPS
-73.76
-56.22
-90.67
-93.36
-107.20
--
Diluted EPS
-73.76
-56.22
-90.67
-99.51
-107.20
--
Basic Average Shares
72,976.97
68,004.20
57,010.35
52,591.73
51,420.30
--
Diluted Average Shares
72,976.97
68,004.20
57,010.35
57,385.05
51,420.30
--
Total Operating Income as Reported
-3,540,000.00
-3,379,000.00
-5,179,000.00
-5,384,000.00
-4,183,000.00
--
Total Expenses
3,665,000.00
3,501,000.00
5,269,000.00
5,425,000.00
4,211,000.00
--
Net Income from Continuing & Discontinued Operation
-5,515,000.00
-3,823,000.00
-5,169,000.00
-4,910,000.00
-5,512,000.00
--
Normalized Income
-5,515,000.00
-3,823,000.00
-5,169,000.00
-4,910,000.00
-5,512,000.00
--
Interest Income
569,000.00
456,000.00
346,000.00
1,728,000.00
1,000.00
--
Interest Expense
2,432,000.00
704,000.00
500,000.00
802,000.00
1,182,000.00
--
Net Interest Income
-1,863,000.00
-248,000.00
-154,000.00
926,000.00
-1,181,000.00
--
EBIT
-2,970,000.00
-2,922,000.00
-4,830,000.00
-3,660,000.00
-4,196,000.00
--
EBITDA
-2,814,000.00
-2,698,000.00
-4,444,000.00
-3,398,000.00
-3,967,000.00
--
Reconciled Cost of Revenue
--
13,000.00
--
--
--
--
Reconciled Depreciation
156,000.00
224,000.00
386,000.00
262,000.00
229,000.00
--
Net Income from Continuing Operation Net Minority Interest
-5,515,000.00
-3,823,000.00
-5,169,000.00
-4,910,000.00
-5,512,000.00
--
Total Unusual Items Excluding Goodwill
--
--
--
--
--
100,000.00
Total Unusual Items
--
--
--
--
--
100,000.00
Normalized EBITDA
-2,814,000.00
-2,698,000.00
-4,444,000.00
-3,398,000.00
-3,967,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
12/31/2019 - 6/16/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6634.TWO Sinew Pharma Inc.
73.20
-7.11%
 
CYP.AX Cynata Therapeutics Limited
0.3000
0.00%
 
MEOBF Mesoblast Limited
0.7900
0.00%
 
ATHXQ Athersys, Inc.
0.0031
-27.06%
 
BRNS Barinthus Biotherapeutics plc
1.9900
+2.58%
 
BCTX BriaCell Therapeutics Corp.
1.3900
-2.80%
 
MSB.AX Mesoblast Limited
1.0450
+1.95%
 
CGTX Cognition Therapeutics, Inc.
1.9500
+5.98%
 
MESO Mesoblast Limited
7.14
+4.69%
 
PYXS Pyxis Oncology, Inc.
3.8000
+7.34%